
Johnson & Johnson's TAR-200 Monotherapy Achieves High Disease-Free Survival Of More Than 80 Percent In BCG-Unresponsive, ...
(MENAFN- PR Newswire) First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 …